JP2017519799A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017519799A5 JP2017519799A5 JP2017500389A JP2017500389A JP2017519799A5 JP 2017519799 A5 JP2017519799 A5 JP 2017519799A5 JP 2017500389 A JP2017500389 A JP 2017500389A JP 2017500389 A JP2017500389 A JP 2017500389A JP 2017519799 A5 JP2017519799 A5 JP 2017519799A5
- Authority
- JP
- Japan
- Prior art keywords
- medicament
- angiotensin
- initial
- use according
- arterial pressure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000005862 Angiotensin II Human genes 0.000 claims description 66
- 101800000733 Angiotensin-2 Proteins 0.000 claims description 66
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 claims description 66
- 229950006323 angiotensin ii Drugs 0.000 claims description 63
- 230000004872 arterial blood pressure Effects 0.000 claims description 62
- 238000000034 method Methods 0.000 claims description 53
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 32
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims description 16
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims description 16
- 229930182837 (R)-adrenaline Natural products 0.000 claims description 16
- 229960003638 dopamine Drugs 0.000 claims description 16
- 229960005139 epinephrine Drugs 0.000 claims description 16
- 229960002748 norepinephrine Drugs 0.000 claims description 16
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims description 16
- 150000003943 catecholamines Chemical class 0.000 claims description 10
- 208000001953 Hypotension Diseases 0.000 claims description 8
- 230000036543 hypotension Effects 0.000 claims description 7
- 238000007911 parenteral administration Methods 0.000 claims description 7
- 238000001802 infusion Methods 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- MPKNWWOXPCCKSV-JZXHSEFVSA-N (2s)-2-[[(2s)-1-[(2s)-2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-5-(diaminomethylideneamino)-2-[[(2s)-2,4-diamino-4-oxobutanoyl]amino]pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1h-imidazol-5-yl)pro Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C1=CC=C(O)C=C1 MPKNWWOXPCCKSV-JZXHSEFVSA-N 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 108010072661 Angiotensin Amide Proteins 0.000 claims description 3
- 101800000734 Angiotensin-1 Proteins 0.000 claims description 3
- 102400000344 Angiotensin-1 Human genes 0.000 claims description 3
- JYPVVOOBQVVUQV-CGHBYZBKSA-N angiotensinamide Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 JYPVVOOBQVVUQV-CGHBYZBKSA-N 0.000 claims description 3
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 3
- 229960004295 valine Drugs 0.000 claims description 3
- 206010053159 Organ failure Diseases 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 206010040070 Septic Shock Diseases 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 206010007625 cardiogenic shock Diseases 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 230000036303 septic shock Effects 0.000 claims description 2
- 230000035939 shock Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 73
- 238000005259 measurement Methods 0.000 claims 30
- 238000004519 manufacturing process Methods 0.000 claims 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 2
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 claims 2
- 102000002852 Vasopressins Human genes 0.000 claims 2
- 108010004977 Vasopressins Proteins 0.000 claims 2
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 229960000310 isoleucine Drugs 0.000 claims 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 2
- 238000011287 therapeutic dose Methods 0.000 claims 2
- 229960003726 vasopressin Drugs 0.000 claims 2
- 208000012866 low blood pressure Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 21
- 230000003247 decreasing effect Effects 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462022054P | 2014-07-08 | 2014-07-08 | |
| US62/022,054 | 2014-07-08 | ||
| PCT/US2015/039499 WO2016007589A1 (en) | 2014-07-08 | 2015-07-08 | Methods for treating hypotension |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020092321A Division JP2020143139A (ja) | 2014-07-08 | 2020-05-27 | 低血圧の治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017519799A JP2017519799A (ja) | 2017-07-20 |
| JP2017519799A5 true JP2017519799A5 (enExample) | 2018-08-16 |
Family
ID=55064810
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017500389A Pending JP2017519799A (ja) | 2014-07-08 | 2015-07-08 | 低血圧の治療方法 |
| JP2020092321A Pending JP2020143139A (ja) | 2014-07-08 | 2020-05-27 | 低血圧の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020092321A Pending JP2020143139A (ja) | 2014-07-08 | 2020-05-27 | 低血圧の治療方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20160074465A1 (enExample) |
| EP (2) | EP3381465A1 (enExample) |
| JP (2) | JP2017519799A (enExample) |
| KR (1) | KR20170026486A (enExample) |
| CN (1) | CN106794224A (enExample) |
| AU (2) | AU2015287955A1 (enExample) |
| BR (1) | BR112017000303A2 (enExample) |
| CA (1) | CA2954016A1 (enExample) |
| EA (2) | EA202091873A3 (enExample) |
| IL (1) | IL249936A0 (enExample) |
| MX (1) | MX2017000306A (enExample) |
| SG (2) | SG10201804034QA (enExample) |
| TW (3) | TW202214219A (enExample) |
| WO (1) | WO2016007589A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9572856B2 (en) | 2009-12-16 | 2017-02-21 | The George Washington University a Congressionally Chartered Not-for-Profit Corporation | Method of treating low blood pressure |
| AU2014364528C1 (en) * | 2013-12-18 | 2021-01-07 | The George Washington University, A Congressional Chartered Not-For-Profit Corporation | Angiotensin ll alone or in combination for the treatment of hypotension |
| US9925233B2 (en) | 2015-01-30 | 2018-03-27 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| KR20180108639A (ko) | 2016-01-07 | 2018-10-04 | 라 졸라 파마슈티칼 컴파니 | 안지오텐신 ii를 투여하는 방법 |
| WO2018191678A1 (en) * | 2017-04-14 | 2018-10-18 | La Jolla Pharmaceutical Company | Methods for administering angiotensin ii |
| WO2019118874A1 (en) * | 2017-12-15 | 2019-06-20 | La Jolla Pharma, Llc | Angiotensin compositions and methods related thereto |
| CA3093725C (en) | 2018-03-23 | 2021-08-24 | Nevakar Inc. | Epinephrine compositions and containers |
| KR102258546B1 (ko) | 2018-10-26 | 2021-06-01 | 양성심 | 유기농 케일을 주 성분으로 하는 건강기능식품 조성물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7115266B2 (en) | 2001-10-05 | 2006-10-03 | Cytos Biotechnology Ag | Angiotensin peptide-carrier conjugates and uses thereof |
| CA2623693A1 (en) * | 2005-09-29 | 2007-04-12 | Fibrogen, Inc. | Methods for reducing blood pressure |
| US20100172862A1 (en) * | 2008-11-28 | 2010-07-08 | Abbott Laboratories | Stable antibody compositions and methods of stabilizing same |
| US9572856B2 (en) * | 2009-12-16 | 2017-02-21 | The George Washington University a Congressionally Chartered Not-for-Profit Corporation | Method of treating low blood pressure |
| AU2014364528C1 (en) * | 2013-12-18 | 2021-01-07 | The George Washington University, A Congressional Chartered Not-For-Profit Corporation | Angiotensin ll alone or in combination for the treatment of hypotension |
-
2015
- 2015-07-08 CA CA2954016A patent/CA2954016A1/en not_active Abandoned
- 2015-07-08 US US14/794,102 patent/US20160074465A1/en not_active Abandoned
- 2015-07-08 SG SG10201804034QA patent/SG10201804034QA/en unknown
- 2015-07-08 CN CN201580048068.XA patent/CN106794224A/zh active Pending
- 2015-07-08 EA EA202091873A patent/EA202091873A3/ru unknown
- 2015-07-08 BR BR112017000303A patent/BR112017000303A2/pt not_active Application Discontinuation
- 2015-07-08 EP EP18158219.8A patent/EP3381465A1/en not_active Withdrawn
- 2015-07-08 EA EA201692534A patent/EA036514B1/ru unknown
- 2015-07-08 KR KR1020177001649A patent/KR20170026486A/ko not_active Ceased
- 2015-07-08 TW TW110149288A patent/TW202214219A/zh unknown
- 2015-07-08 SG SG11201610897VA patent/SG11201610897VA/en unknown
- 2015-07-08 TW TW104122255A patent/TWI688385B/zh active
- 2015-07-08 EP EP15775357.5A patent/EP3007722A4/en not_active Ceased
- 2015-07-08 TW TW109105582A patent/TWI754225B/zh active
- 2015-07-08 MX MX2017000306A patent/MX2017000306A/es unknown
- 2015-07-08 JP JP2017500389A patent/JP2017519799A/ja active Pending
- 2015-07-08 WO PCT/US2015/039499 patent/WO2016007589A1/en not_active Ceased
- 2015-07-08 AU AU2015287955A patent/AU2015287955A1/en not_active Abandoned
-
2017
- 2017-01-05 IL IL249936A patent/IL249936A0/en unknown
-
2018
- 2018-06-22 US US16/016,088 patent/US20180311306A1/en not_active Abandoned
-
2020
- 2020-04-17 US US16/851,695 patent/US20200237853A1/en not_active Abandoned
- 2020-05-27 JP JP2020092321A patent/JP2020143139A/ja active Pending
-
2021
- 2021-03-17 AU AU2021201669A patent/AU2021201669A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017519799A5 (enExample) | ||
| JP2016516016A5 (enExample) | ||
| CA2923685A1 (en) | Application of r-ketamine and salt thereof as pharmaceuticals | |
| JP2017510607A5 (enExample) | ||
| NZ598534A (en) | Dosage regimen of an s1p receptor modulator | |
| RU2015134581A (ru) | Доноры нитроксила с улучшенным терапевтическим индексом | |
| JP2017501154A5 (enExample) | ||
| RU2014141893A (ru) | Применение производной пиразола в лечении острых приступов хронической обструктивной болезни легких | |
| JP2019504012A5 (enExample) | ||
| JP2016517421A5 (enExample) | ||
| JP2014511365A5 (enExample) | ||
| JP2020536121A5 (enExample) | ||
| PH12015502465A1 (en) | Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias | |
| JP2019507786A5 (enExample) | ||
| JP2016505050A5 (enExample) | ||
| FI3352735T3 (fi) | Pitkitetysti vapauttavia olantsapiiniformulaatioita | |
| WO2022039619A1 (ru) | Противовирусное средство для комбинированной терапии covid-19 (sars-cov-2) | |
| JP2016520114A5 (enExample) | ||
| JP2018502924A5 (enExample) | ||
| JP2016510040A5 (enExample) | ||
| KR20170118830A (ko) | 조현병의 치료를 위한 일로페리돈 | |
| CN108472375A (zh) | 中重度流感的治疗方法 | |
| CN114588164B (zh) | 瑞马唑仑在预防围术期低体温和寒战中的应用 | |
| RU2742116C1 (ru) | Противокоронавирусное средство для комбинированной терапии COVID-19 (SARS-CoV-2). | |
| RU2745986C1 (ru) | Противокоронавирусное средство для комбинированной терапии COVID-19 (SARS-CoV-2) и способ лечения |